NASDAQ:GALT

Galectin Therapeutics Q3 2026 Earnings Results & Report

Galectin Therapeutics logo
$2.91 -0.11 (-3.64%)
As of 11/17/2026 04:00 PM Eastern

Galectin Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.04 versus the -$0.05 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Galectin Therapeutics EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Galectin Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galectin Therapeutics Q3 2026 Earnings FAQ

Galectin Therapeutics (NASDAQ:GALT) reported earnings of -$0.04 per share for Q3 2026, beating the consensus estimate of -$0.05. The report was announced on Monday, November 16, 2026.

Galectin Therapeutics Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Galectin Therapeutics Inc GALT
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT) is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer.

Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

The company was previously known as Pro-Pharmaceuticals before adopting the Galectin Therapeutics name. Its work is centered on drug research and clinical development rather than the sale of marketed medicines.

View Galectin Therapeutics Profile